摘要
以北京生物制品研究所引进美国Ｍｅｒｃｋ公司基因工程技术生产的重组酵母乙型肝炎（乙肝）疫苗，阻断乙肝病毒的母婴传播，结果ＨＢｓＡｇ、ＨＢｓＡｇ双阳性孕妇分娩的新生儿，全程免疫后７个月和１２个月的保护率分别为９６．７％和９６．０％；抗－ＨＢｓ阳转率分别为９４．７％、９３．５％；ＧＭＴ分别为６６．６ｍＩＵ／ｍｌ、７６．６ｍＩＵ／ｍｌ。优于血源性乙肝疫苗。
he protective efficacy and immunogenicity of recombinant yeast-derived hepatitis Bvaccine(DV),produced by our institute,was implemented for newborns whose motherswere both HBsAg and HBeAg positive. 38 infants were immunized with three doses of YDV(5μ g/0.5ml)by 0,1,6 month schedule after birth.After three doses,one of them was HBsAgpositive,the protective rate of prevention of perinatal transmission was 96.7%. At 7 and 12 monthsold,the seroconversion rates and geometric mean anti-HBs titres were 94.7 % and 66.6mIU/ml,93.5 % and 76.6mIU/ml respectively. The results showed that the YDV was effective.
出处
《中国计划免疫》
1996年第2期67-69,共3页
Chinese Journal of Vaccines and Immunization
关键词
重组酵母
乙型肝炎
疫苗
母婴传播
阻断
Recobinant yeast-derived hepatitis B vaccine,Protective efficacy,Prevention of perinatal transmission
